Optimizing CAR T-Cell Therapy After Bispecific Antibody Treatment for Multiple Myeloma
The treatment landscape for relapsed/refractory multiple myeloma (RRMM) has been significantly altered by the introduction of both CAR T-cell therapy and bispecific antibodies. Even as both modalities demonstrate impressive clinical efficacy, determining the optimal sequencing of these treatments remains a key challenge for clinicians. Recent insights emphasize that prior exposure to bispecific antibodies doesn’t necessarily preclude a patient from receiving CAR T-cell therapy, but careful evaluation is crucial to maximize treatment success.
The Impact of Bispecific Antibodies on CAR T-Cell Eligibility
Bispecific antibodies, which engage T cells to target plasma cells expressing antigens like BCMA, GPRC5D and FcRH5, have become important therapeutic options in RRMM 1. However, the timing of bispecific antibody exposure relative to CAR T-cell therapy is a critical consideration. Prolonged exposure to bispecific antibodies can lead to T-cell exhaustion, potentially compromising the quality of T-cell collection and ultimately diminishing the response to CAR T-cell therapy.
Assessing Patient Readiness for CAR T-Cell Therapy
Clinical judgment plays a central role in determining CAR T-cell candidacy following bispecific antibody treatment. Factors considered include the tempo of the disease, the duration since the patient last received a bispecific antibody, and an assessment of residual T-cell fitness. Additional assessments are similarly vital:
- Infection Monitoring: Screening for infections, such as cytomegalovirus (CMV), is essential before proceeding with CAR T-cell therapy.
- Immunoglobulin Levels: Evaluating immunoglobulin levels provides insights into the patient’s immune status.
- Advanced Sequencing & Biomarkers: Utilizing sequencing tools or monitoring soluble BCMA levels, when available, can offer further guidance.
Practical Considerations and Patient Expectations
Beyond clinical assessments, managing patient expectations is paramount. The process from referral to authorization, apheresis (T-cell collection), manufacturing, and final infusion can be lengthy. Even with streamlined processes, patients should be prepared for a significant time commitment away from work. Clear and proactive communication is essential to ensure a smooth and informed experience.
Current Approved Therapies
As of 2025, there are two approved BCMA-targeted CAR T-cell therapies: idecabtagene vicleucel and ciltacabtagene autoleucel 2, 3. Four commercially available bispecific antibodies target BCMA (teclistamab, elranatamab, and linvoseltamab) and GPRC5D (talquetamab) 3.
Future Directions
Ongoing research focuses on optimizing the sequencing of CAR T-cell therapy and bispecific antibodies to maximize long-term outcomes in multiple myeloma. Efforts are also underway to address resistance mechanisms, such as T-cell exhaustion and target antigen loss, and to explore the potential of these therapies in earlier lines of treatment 1.
The post CAR T-Cell Therapy After Bispecifics: Patient Selection & Readiness appeared first on Archynewsy.